Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
À¶Ý®ÊÓƵ
Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2 Stuver, R., Michaud, L., Casulo, C., Advani, R. H., Budde, E. L., Barr, P. M., Batlevi, C., Caron, P. C., Constine, L. S., Dandapani, S., Drullinsky, P., Friedberg, J. W., Grieve, C., Hamilton, A., Hamlin, P. A., Hoppe, R., Horwitz, S. M., Khan, N., Matasar, M. J., Noy, A., Palomba, M., Schoder, H., Straus, D. J., Vemuri, S., Yahalom, J., Yang, J. C., Younes, A., Zelenetz, A. D., Moskowitz, C. H., Kumar, A., Moskowitz, A. J. AMER SOC HEMATOLOGY. 2022: 1756-1758View details for
View details for